AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double‐blind, efficacy, and safety study.

Autor: van Laar, Jacob M.¹ (AUTHOR) j.m.vanlaar@umcutrecht.nl, Lei, Alejhandra² (AUTHOR), Safy‐Khan, Mary¹ (AUTHOR), Almquist, Joachim³ (AUTHOR), Belfield, Graham⁴ (AUTHOR), Edman, Karl⁵ (AUTHOR), Öberg, Lisa⁶ (AUTHOR), Angermann, Bastian R.⁶ (AUTHOR), Dillmann, Inken⁴ (AUTHOR), Berntsson, Pia⁷ (AUTHOR), Etal, Damla⁴ (AUTHOR), Dainty, Ian⁷ (AUTHOR), Astbury, Carol⁸ (AUTHOR), Belvisi, Maria G.^9,10 (AUTHOR), Nemes, Szilárd¹¹ (AUTHOR), Platt, Adam¹² (AUTHOR), Prothon, Susanne³ (AUTHOR), Samuelsson, Sara¹³ (AUTHOR), Svanberg, Petter¹⁴ (AUTHOR), Keen, Christina¹³ (AUTHOR)

Publikováno v: CTS: Clinical & Translational Science. Dec2023, Vol. 16 Issue 12, p2494-2506. 13p.

POS0089 AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY

Autor: Alejhandra Lei, Petter Svanberg, S. Samuelsson, C. Astbury, Christina Keen, Susanne Prothon, Maria G. Belvisi, Joachim Almquist, J.M. van Laar, Adam Platt, M. Safy-Khan

Publikováno v: Annals of the Rheumatic Diseases. 80:253-254

Background:Oral corticosteroids such as prednisolone are potent anti-inflammatory drugs but their use is limited by side effects caused by unwanted actions on the glucocorticoid receptor (GR), such as increased insulin resistance, and off-target acti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::156db222420c250675fb3942ed7ee88a
https://doi.org/10.1136/annrheumdis-2021-eular.632

POSTERS.

Publikováno v: Diabetes; Jun2003 Supplement, Vol. 52, pA81-A432, 352p, 4 Diagrams, 270 Charts, 53 Graphs